SCHEMBL33526829

SCHEMBL33526829

Cc1cn2c(C(N)=O)c(Br)sc2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
TGFBR1 P36897 1/20 0.33
LIMK1 P53667 3/20 0.33
IKBKB O14920 2/20 0.33
DAPK3 O43293 1/20 0.33
CSNK1A1 P48729 1/20 0.33
TNK2 Q07912 1/20 0.33
ROCK1 Q13464 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
TSHR P16473 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
CHUK O15111 1/20 0.32
PRKACA P17612 1/20 0.32
PRKACG P22612 1/20 0.32
PRKACB P22694 1/20 0.32
BTK Q06187 1/20 0.32
POLB P06746 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL33526512 0.81 DAPK3 (0.35) NPC1MAPTRAB9ADAPK3CSNK1A1
SCHEMBL31432819 0.65 MAPT (0.38) NPC1MAPTRAB9ATSHRALDH1A1
SCHEMBL954299 0.65 EPHB3 (0.56) NPC1MAPTRAB9ATGFBR1POLB
SCHEMBL20376570 0.62 PTGS2 (0.44) NPC1MAPTRAB9ATGFBR1NPSR1
SCHEMBL13834891 0.62 SCN9A (0.38) LIMK1DAPK3CSNK1A1TNK2ROCK1
SCHEMBL21196913 0.61 MAPK9 (0.47) MAPTRAB9AMAPK9MAPK10ALDH1A1
SCHEMBL19723761 0.61 TGFBR1 (0.47) NPC1MAPTRAB9ATGFBR1CSNK1A1
SCHEMBL18773508 0.61 SCN9A (0.40) NPC1MAPTRAB9ATGFBR1LIMK1
SCHEMBL24619400 0.61 LMNA (0.42) NPC1MAPTRAB9AALDH1A1
SCHEMBL30722107 0.61 LMNA (0.42) NPC1MAPTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091048-A1 GIP RECEPTOR AGONIST COMPOUNDS LILLY CO ELI (US) 2026-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260091048-A1 GIP RECEPTOR AGONIST COMPOUNDS GIPR, GLP1R, GPR119 NPC1 802/4885MAPT 4878/4885RAB9A 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.